期刊
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS
卷 21, 期 5, 页码 545-551出版社
ADIS INT LTD
DOI: 10.1007/s40256-021-00470-0
关键词
-
This study compared the safety and efficacy of DOACs in patients with NVAF weighing >= 120 kg with those weighing < 120 kg. The results suggest that apixaban, dabigatran, or rivaroxaban may be well-tolerated and effective anticoagulant options in patients with NVAF weighing >= 120 kg.
Background Direct oral anticoagulants (DOACs) have become favorable choices for anticoagulation due to their fixed-dose schedule, limited need for monitoring, and non-inferiority or superiority to warfarin. DOACs are currently not recommended in patients with a body weight >= 120 kg or body mass index >= 40 kg/m(2) due to limited data regarding safety and efficacy. Objective The aim of this study was to compare the safety and efficacy of DOACs in patients with nonvalvular atrial fibrillation (NVAF) and weighing >= 120 kg with those weighing Methods A single-center, retrospective study was conducted in patients weighing >= 120 kg who received either apixaban, dabigatran, or rivaroxaban for stroke risk reduction in NVAF, and matched to patients who weighed < 120 kg. The primary outcome was the incidence of stroke, deep vein thrombosis, pulmonary embolism, or myocardial infarction, while the safety outcome was the incidence of major or clinically relevant non-major bleeding based on the International Society on Thrombosis and Haemostasis (ISTH) definitions. Results A total of 318 patients weighing >= 120 kg with NVAF and meeting the inclusion criteria were evaluated and matched with 318 patients weighing < 120 kg. The primary outcome occurred in 2.5% of patients in the >= 120 kg group and in 3.1% of patients in the < 120 kg group (p = 0.632). The safety outcome occurred in 5.3% and 6.6% of patients in these respective groups (p = 0.503). Conclusion Apixaban, dabigatran, or rivaroxaban may be well-tolerated and effective anticoagulant options in patients with NVAF weighing >= 120 kg.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据